【摘要】 目的 通过对分别采用速避凝和丹参治疗的两组缺血性脑卒中患者血浆中的基质金属蛋白酶-9(MMP-9)水平的测定,探讨速避凝和丹参对缺血性脑卒中患者血浆中MMP-9含量的影响。方法 选取32例发病时间在24小时内的脑卒中急性期病例,按年龄匹配原则随机分成速避凝组16例,丹参组16例;采用酶联免疫吸附检测方法(ELISA)测定脑缺血后24小时内、第3天和第7天时血浆中MMP-9的含量。结果 脑缺血后24小时内(治疗前)、治疗后第3天和第7天时两组血浆内MMP-9含量都在上升;第3天和第7天时的含量均比发病时显著升高(P<0.001),第7天的含量比第3天的含量略高一点,但无明显差异(P>0.05);速避凝组治疗后3天内MMP-9含量增加值小于相同时间的丹参治疗组(P<0.05);7天内MMP-9水平上升值两组之间无显著差异(P=0.297)。结论 速避凝与丹参不能抑制或阻止缺血性脑卒中患者血浆中MMP-9含量上升;与丹参治疗组相比,速避凝能减少患者血浆中早期MMP-9含量的增加。更多还原

【Abstract】 Objective To investigate the effects of Fraxiparine and Danshen on matrix metalloproteinase-9 (MMP-9) levels in patients with cerebral ischaemic stroke by measuring plasma MMP-9 levels of plasma. Methods The plasma was obtained from 32 acute cerebral ischaemic stroke patients, which was assigned randomly into Fraxiparine group or Danshen group, before, and in 3, 7 days after treatment. The MMP-9 levels of plasma were detected by ELISA. Results The MMP-9 levels in patients with acute stroke increased in both Fraxiparine group and Danshen group, the third day and the 7th day’s MMP-9 levels after treatment were all significantly higher than those before treatment in two groups (P<0.001). Before treatment, there was no difference of MMP-9 levels between in Fraxiparine group and in Danshen group (P>0.05). The increased levels was fewer in Fraxiparine group than in Danshen group at 3 days after treatment (P<0.05). Conclusions Fraxiparine or Danshen can not inhibit the increased MMP-9 levels after ischemic stroke. But compared with Danshen, Fraxiparine can decrease the increase of MMP-9 in the early days.更多还原